FDA Reverses Feb-10 Refusal, Accepts Moderna mRNA-1010 Flu Vaccine for Review

Regulatory flip-flops are not new: in 1955 the FDA halted Salk polio vaccine lots after the Cutter Incident, only to resume licensure weeks later once safety criteria tightened. Today’s mRNA-1010 reversal echoes that tension between rapid innovation and institutional caution. The episode sits at the crossroads of two long-term arcs—the century-long expansion of adult immunization (from the first flu shot in 1945 to the high-dose Fluzone in 2009) and the post-COVID politicization of mRNA technology. By publicly over-ruling its own vaccine chief after industry and media pressure, the FDA signals a shift back toward risk-tolerant biotechnological competition even as top officials defund mRNA research. Whether this moment accelerates acceptance of nucleic-acid platforms or entrenches skepticism will shape seasonal-flu control and pandemic readiness over the next hundred years, when speed of antigen update may matter more than today’s comparator debates.